<DOC>
	<DOCNO>NCT02713529</DOCNO>
	<brief_summary>A multi-center Phase 1b/2 study test combination AMG 820 pembrolizumab subject select advanced solid tumor .</brief_summary>
	<brief_title>Safety Efficacy Study AMG 820 Pembrolizumab Combination Select Advanced Solid Tumor Cancer</brief_title>
	<detailed_description>Phase 1b AMG 820 dose determine aim assess safety tolerability select start dose AMG 820 combination pembrolizumab . Phase 2 study evaluate safety tolerability additionally test whether AMG 820 enhance anti-tumor activity observe historically pembrolizumab alone and/or overcome lack response pembrolizumab monotherapy subject select solid tumor .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Pathologically document , advanced colorectal , pancreatic nonsmall cell lung cancer refractory standard treatment , subject intolerant refuse standard treatment . Measurable disease per RECIST 1.1 guideline . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematologic , renal , hepatic function determine laboratory blood urine test . Availability recent tumor tissue 3 month prior enrollment , feasible . Has know active central nervous system metastases History malignancy past 2 year exception Evidence active noninfectious pneumonitis/interstitial lung disease Evidence active autoimmune disease require prolonged systemic treatment past 2 year . Evidence clinically significant immunosuppression organ stem cell transplantation , severe congenital acquire cellular and/or humoral immune deficiency , concurrent opportunistic infection . Receiving systemic immunostimulatory agent within 6 week 5 halflives , whichever short , prior first dose study treatment ( except ant PD1/PDL1 treatment recruit Group 4a 4b ) . Evidence active infection within 2 week prior first dose study treatment . Prior chemotherapy , radiotherapy , biological cancer therapy major surgery within 28 day prior enrollment Currently participate participate study ( treatment period ) investigational agent use investigational device within 28 day enrollment Received live vaccine within 28 day prior enrollment Adverse event due cancer therapy administer 28 day prior enrollment recover CTCAE grade 1 well . Positive human immunodeficiency virus ( HIV ) , Hepatitis B C Women plan become pregnant lactating/breastfeeding study 4 month receive last dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Solid Tumor</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>